Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

FDA drug approval stories

Nov 16, 2026

FDA approves Roche's oral breast cancer pill Wilserdly

The FDA approved Roche's oral treatment for estrogen receptor-positive, HER2-negative advanced breast cancer, providing a new option for patients and a significant commercial boost for the Swiss drugmaker.

Nov 16, 2026·3 sources
00
Nov 15, 2026

FDA rejects Summit Therapeutics and Akeso's ivonescimab for lung cancer

The FDA declined to approve ivonescimab, a bispecific antibody from Summit Therapeutics and Akeso, after the trial missed its key overall survival endpoint in a narrow lung cancer setting. Analysts had largely anticipated the rejection.

Nov 15, 2026·2 sources
00
Nov 13, 2026

FDA approves durvalumab plus enfortumab vedotin for muscle-invasive bladder cancer

The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.

Nov 13, 2026·2 sources
00

Novo submits sickle cell drug for regulatory approval

Novo Nordisk has submitted a sickle cell disease drug for regulatory approval, a medicine acquired in a billion-dollar deal that the company views as a future blockbuster.

Nov 13, 2026·2 sources
00
Nov 12, 2026

FDA quietly shelves Trump's drug fast-track voucher program amid agency chaos

No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.

Nov 12, 2026·2 sources
00
Nov 10, 2026

FDA approves Merck KGaA's pimicotinib for tenosynovial giant cell tumor

The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.

Nov 10, 2026·3 sources
00
Nov 9, 2026

FDA approves Bayer's asundexian as first-in-class factor XIa inhibitor for stroke prevention

The FDA approved asundexian (Sunharbo), a novel blood thinner from Bayer, to reduce the risk of recurrent stroke in adults, marking the first approval in the factor XIa inhibitor class.

Nov 9, 2026·6 sources
00
Nov 6, 2026

Moderna posts first quarterly profit in two years, raises revenue forecast

Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.

Nov 6, 2026·5 sources
00
Nov 5, 2026

FDA grants J&J accelerated approval for head and neck cancer treatment

The FDA granted accelerated approval to Johnson & Johnson's treatment for patients with advanced head and neck cancer whose disease has worsened after prior therapy.

Nov 5, 2026·2 sources
00

Revolution Medicines' pancreatic cancer drug Rasonque posts record launch

Revolution Medicines' RAS inhibitor Rasonque is tracking as the best cancer drug launch in history by early sales metrics, with Wall Street analysts resetting projections upward. Company executives cautioned it is too early to draw firm conclusions.

Nov 5, 2026·3 sources
00
Nov 2, 2026

FDA approves generic version of HIV-prevention shot lenacapavir

The U.S. Food and Drug Administration has approved a generic version of the world's only twice-a-year shot to prevent HIV, a significant step toward making the drug available inexpensively and more quickly in low-income countries.

Nov 2, 2026·2 sources
00

FDA sets May 2027 review date for uniQure's Huntington's gene therapy

The FDA will review uniQure's gene therapy for Huntington's disease, with a decision expected in May 2027. The agency has also scheduled an advisory committee meeting.

Nov 2, 2026·2 sources
00
Oct 30, 2026

FDA approves Inovio's Voceryq for recurrent respiratory papillomatosis

The U.S. Food and Drug Administration has approved Inovio Pharmaceuticals' treatment Voceryq for recurrent respiratory papillomatosis, a rare throat disease. The approval sent Inovio's shares surging.

Oct 30, 2026·4 sources
00

FDA approves tildrakizumab for psoriatic arthritis

The FDA cleared Sun Pharma's interleukin-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis in adults, expanding the drug's approved indications.

Oct 30, 2026·3 sources
00

FDA advisory committee reviews SYD-101 atropine eye drops for pediatric myopia

An FDA advisory committee convened on October 30 to discuss SYD-101, a low-dose atropine eye drop for slowing pediatric myopia that the FDA declined to approve last year. The treatment met its primary endpoint in a phase 3 trial, but the FDA determined the overall results were insufficient for approval.

Oct 30, 2026·1 source
00
Oct 26, 2026

Merck drug extends survival in endometrial cancer, wins FDA priority review

Merck's experimental antibody-drug conjugate reduced death risk by one-third in advanced endometrial cancer patients and received FDA priority review based on late-stage trial data.

Oct 26, 2026·3 sources
00

FDA expands talazoparib approval for metastatic prostate cancer

The FDA approved the PARP inhibitor talazoparib in combination with enzalutamide for treatment of patients with metastatic androgen pathway modulation-naive or -sensitive prostate cancer.

Oct 26, 2026·2 sources
00
Oct 22, 2026

FDA approves dolutegravir HIV drug for newborns based on international clinical trial

The U.S. Food and Drug Administration has approved dolutegravir, a second-generation antiretroviral drug, for use in newborns exposed to HIV-1. The approval was informed by an international phase 1 study conducted through the IMPAACT Network that established safe and effective dosing regimens for full-term neonates.

Oct 22, 2026·3 sources
00
Oct 21, 2026

Roivant's brepocitinib succeeds in phase 3 trials for non-infectious uveitis

Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.

Oct 21, 2026·7 sources
00
Oct 20, 2026

FDA approves GSK's hepatitis B drug Hibsago

The FDA approved GSK's hepatitis B drug Hibsago, allowing patients with the liver infection to maintain viral control after stopping long-term treatment. The approval offers a new treatment option for chronic hepatitis B patients.

Oct 20, 2026·2 sources
00
Oct 19, 2026

FDA approves Ryzumvi eye drops for presbyopia

The FDA has approved Ryzumvi (phentolamine 0.75%) eye drops to treat presbyopia in adults, marking a label expansion for the product marketed by Viatris.

Oct 19, 2026·3 sources
00
Oct 16, 2026

Satralizumab approved as first at-home treatment for thyroid eye disease

The FDA has approved satralizumab (Enspryng) as the first self-administered therapy for thyroid eye disease, expanding treatment options beyond the existing intravenous therapies.

Oct 16, 2026·2 sources
00
Oct 14, 2026

FDA expands Anktiva approval for bladder cancer treatment

The FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer, expanding the drug's approved indications.

Oct 14, 2026·2 sources
00
Oct 9, 2026

FDA approves atezolizumab with chemotherapy for stage III colon cancer

The FDA has approved atezolizumab (Tecentriq) in combination with chemotherapy as adjuvant treatment for adult and pediatric patients aged 2 years or older with stage III mismatch repair-deficient colon cancer.

Oct 9, 2026·2 sources
00
Oct 7, 2026

FDA approves Pfizer's TUKYSA as first-line maintenance treatment for HER2+ metastatic breast cancer

The FDA approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with HER2-positive metastatic breast cancer. The approval was supported by data showing more than 50% improvement in median progression-free survival.

Oct 7, 2026·4 sources
00

FDA expands Novartis remibrutinib approval for symptomatic dermographism

The FDA approved remibrutinib to treat adults with symptomatic dermographism inadequately controlled with H1 antihistamines, expanding the drug's indication beyond its initial approval.

Oct 7, 2026·2 sources
00
Oct 2, 2026

Pirtobrutinib wins FDA approval for frontline CLL/SLL treatment

The FDA expanded approval of pirtobrutinib, a non-covalent BTK inhibitor, for chronic lymphocytic leukemia and small lymphocytic lymphoma in the frontline setting.

Oct 2, 2026·2 sources
00
Oct 1, 2026

FDA approves Camzyos for pediatric hypertrophic cardiomyopathy, first cardiac myosin inhibitor for children

The FDA has approved Bristol Myers Squibb's Camzyos (mavacamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients, making it the first cardiac myosin inhibitor approved for children with this painful heart condition. The approval is based on positive results from the Phase 3 SCOUT-HCM trial.

Oct 1, 2026·5 sources
00
Sep 28, 2026

FDA approves baricitinib for adolescents with severe alopecia areata

The FDA has expanded the indication for baricitinib (Olumiant), a once-daily oral JAK inhibitor, to include adolescents aged 12 and older with severe alopecia areata. This marks the second JAK inhibitor treatment approved for adolescents with the condition.

Sep 28, 2026·3 sources
00

FDA approves obinutuzumab for idiopathic nephrotic syndrome, first new treatment in 70 years

The FDA has approved Roche's obinutuzumab (Gazyva), an anti-CD20 agent, for treating idiopathic nephrotic syndrome in patients as young as 2 years old. This marks the first new drug approval for this kidney condition in seven decades.

Sep 28, 2026·2 sources
00

FDA approves AbbVie's Juvmo, first D1/D5 dopamine agonist for Parkinson's disease

The FDA has approved Juvmo (tavapadon), the first and only dopamine agonist designed to selectively target D1/D5 receptors for treating adults with Parkinson's disease. The once-daily oral tablet can be taken with or without levodopa therapy and came from AbbVie's $8.7 billion acquisition of Cerevel Therapeutics.

Sep 28, 2026·5 sources
00
Sep 25, 2026

FDA approves Mirum Pharmaceuticals' Atebrioz for fibrodysplasia ossificans progressiva

The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib), a once-daily pill for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes soft tissue to turn to bone. This marks the third FDA-approved treatment for FOP, following recent approvals of Regeneron's Pasatru and Ipsen's Sohonos.

Sep 25, 2026·6 sources
00
Sep 24, 2026

FDA approves Eli Lilly's Onswik once-weekly insulin for type 2 diabetes

The U.S. Food and Drug Administration has approved Eli Lilly's Onswik, a once-weekly basal insulin injection for adults with type 2 diabetes. The approval offers patients an alternative to daily long-acting insulin injections, potentially reducing the number of injections by more than 300 per year.

Sep 24, 2026·5 sources
00

Kyverna Therapeutics reports one-year durability data for autoimmune cell therapy

Kyverna Therapeutics released one-year follow-up data showing patients with stiff person syndrome remained off other therapies after treatment with its CAR-T cell therapy miv-cel. The company plans to file for FDA priority review this year, which would make it the first cell therapy approved for an autoimmune disease.

Sep 24, 2026·4 sources
00
Sep 23, 2026

FDA approves Elevar Therapeutics' Lyrfigtu for bile duct cancer with FGFR2 alterations

The FDA has approved Lyrfigtu (lirafugratinib) as a second-line treatment for cholangiocarcinoma (bile duct cancer) with FGFR2 fusion or other rearrangements. The drug demonstrated a 46% confirmed objective response rate and median duration of response of 11.8 months in clinical trials.

Sep 23, 2026·2 sources
00
Sep 21, 2026

FDA approves IntraBio's AQNEURSA as first treatment for ataxia-telangiectasia

The U.S. FDA has approved AQNEURSA (levacetylleucine) as the first and only approved treatment for ataxia-telangiectasia (A-T) in the United States or anywhere in the world. This marks the second FDA-approved indication for AQNEURSA.

Sep 21, 2026·2 sources
00
Sep 17, 2026

FDA approves Ultragenyx's Fayuvi, first gene therapy for Sanfilippo syndrome type A

The FDA granted full approval to Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A, marking the first-ever approved treatment for the ultra-rare, fatal neurodegenerative disease. The approval comes after a previous regulatory rejection and represents a significant milestone for patients with this devastating condition.

Sep 17, 2026·4 sources
00
Sep 15, 2026

FDA approves first radioligand equivalent, Curium's copycat of Novartis' Lutathera

The FDA has approved Curium's Bexlutry (lutetium Lu 177 dotatate injection), marking the industry's first radioligand equivalent and setting up the first generic competition for Novartis in the radioligand therapy field. The approval came after a court cleared Curium of all patent claims.

Sep 15, 2026·2 sources
00

FDA approves floretyrosine F18 PET imaging agent for glioma diagnosis

The FDA has approved floretyrosine F18 (Pixclara, Telix Pharmaceuticals), an intravenous PET imaging agent designed to differentiate recurrent or progressive glioma from treatment-related changes in brain tissue.

Sep 15, 2026·1 source
00
Sep 14, 2026

Scholar Rock's spinal muscular atrophy drug Isembyld approved by FDA

The FDA approved Isembyld (apitegromab), the first muscle-targeted treatment for spinal muscular atrophy. The drug will cost approximately $310,000 annually and showed improvements in motor function in clinical trials.

Sep 14, 2026·3 sources
00
Sep 12, 2026

FDA expands approval for sevabertinib to frontline treatment of HER2-mutant advanced NSCLC

The US Food and Drug Administration has granted expanded accelerated approval for sevabertinib as a frontline treatment option for patients with HER2-mutant advanced non-small cell lung cancer, with nursing management focusing on diarrhea monitoring.

Sep 12, 2026·1 source
00
Sep 11, 2026

Scholar Rock receives first FDA approval for rare muscle-wasting disease therapy

The FDA approved Scholar Rock's therapy to treat a rare genetic condition causing muscle weakness, marking the first regulatory approval for the company and the first treatment for this specific disease.

Sep 11, 2026·2 sources
00
Sep 10, 2026

Takeda R&D chief Andy Plump to retire in June 2027

Andy Plump, who led Takeda's research and development overhaul and pushed the company toward biotech partnerships, will retire in June 2027 after celebrating two recent FDA approvals.

Sep 10, 2026·2 sources
00
Sep 8, 2026

FDA approves AstraZeneca's camizestrant for breast cancer despite advisory panel rejection

The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) for breast cancer treatment, marking a rare divergence from its expert advisory panel's recommendation and opening a new ctDNA-guided treatment paradigm.

Sep 8, 2026·3 sources
00
Sep 7, 2026

FDA approves AstraZeneca's camizestrant for breast cancer despite negative advisory committee vote

The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) in combination with CDK4/6 inhibitors for ESR1-mutated breast cancer, overriding a negative advisory committee recommendation.

Sep 7, 2026·2 sources
00
Sep 3, 2026

Ionis Pharmaceuticals wins FDA approval for first Alexander disease treatment, priced at $285,000 per dose

The FDA approved Zanvastro, an antisense oligonucleotide therapy from Ionis Pharmaceuticals, as the first targeted treatment for Alexander disease, a rare and deadly genetic neurological disorder affecting adults and children. The company priced the injectable drug at $285,000 per dose.

Sep 3, 2026·5 sources
00
Aug 28, 2026

FDA approves Priovant's Lisraya for rare inflammatory disorder dermatomyositis

The FDA approved Roivant Sciences subsidiary Priovant Therapeutics' Lisraya as a once-daily pill treatment for dermatomyositis, a rare inflammatory disorder. The drug was licensed from Pfizer.

Aug 28, 2026·3 sources
00

Priovant receives first FDA approval for targeted tablet in dermatomyositis

Priovant Therapeutics secured its first FDA approval for a targeted tablet treatment for dermatomyositis, a rare autoimmune disease affecting muscles and skin.

Aug 28, 2026·2 sources
00

FDA Approves Stelara for Pediatric Ulcerative Colitis

The FDA approved ustekinumab (Stelara) on August 28, 2026 for the treatment of moderately to severely active ulcerative colitis in pediatric patients aged 2 years and older, making it the first non-TNF biologic approved for pediatric IBD.

Aug 28, 2026·1 source
00
Aug 26, 2026

RevMed's pancreatic cancer pill daraxonrasib wins FDA approval at $475,000 annual cost

Revolution Medicines' breakthrough pill targeting KRAS mutations in advanced pancreatic cancer received FDA approval, priced at over $475,000 per year. The drug nearly doubles survival in patients with this hard-to-treat cancer.

Aug 26, 2026·2 sources
00
Aug 20, 2026

Ultragenyx wins first gene therapy approval with Genglycos for glycogen storage disease

The FDA approved Ultragenyx's Genglycos gene therapy for a rare glycogen storage disease, marking the company's first gene therapy clearance and providing a priority review voucher.

Aug 20, 2026·4 sources
00
Aug 14, 2026

FDA approves Enigma Biomedical's TAUKLARIFY for Alzheimer's disease diagnosis

The FDA has approved TAUKLARIFY (florquinitau F 18 injection), a novel diagnostic imaging agent developed by Enigma Biomedical USA to identify tau neurofibrillary tangles in patients being evaluated for Alzheimer's disease, including tangles isolated to the medial temporal lobe.

Aug 14, 2026·1 source
00

FDA approves Bristol Myers Squibb's Zenbexus, first CELMoD drug for multiple myeloma

The FDA has approved Zenbexus (iberdomide) for multiple myeloma treatment, marking the first approval in the novel CELMoD drug class that uses targeted protein degradation. Bristol Myers Squibb acquired the therapy through its Celgene acquisition and is positioning it as a successor to its legacy myeloma products.

Aug 14, 2026·4 sources
00
Aug 6, 2026

Malaria Research Advances on Multiple Fronts as Drug Resistance Grows and New Vaccine Technologies Emerge

Scientists report progress in malaria vaccine development with new antibody-targeting approaches, while separate research reveals increasingly sophisticated drug resistance in malaria parasites. Meanwhile, FDA approval of Moderna's mRNA flu vaccine strengthens the case for applying mRNA technology to malaria and other diseases.

Aug 6, 2026·3 sources
00

Malaria Research Advances on Multiple Fronts as Drug Resistance Grows and New Vaccine Technologies Emerge

Scientists report progress in malaria vaccine development with new antibody-targeting approaches, while separate research reveals increasingly sophisticated drug resistance in malaria parasites. Meanwhile, FDA approval of Moderna's mRNA flu vaccine strengthens the case for applying mRNA technology to malaria and other diseases.

Aug 6, 2026·3 sources
00

FDA approves Moderna's mFlusiva, first mRNA-based flu vaccine in the United States

The Food and Drug Administration approved Moderna's mFlusiva on Wednesday, marking the first mRNA-based influenza vaccine authorized in the U.S. The vaccine is approved for adults aged 50 and older, representing a significant expansion of mRNA technology beyond COVID-19 vaccines.

Aug 6, 2026·6 sources
00
Aug 2, 2026

FDA expands Pluvicto approval for earlier-stage metastatic prostate cancer treatment

The FDA has approved Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use in combination with hormone therapy for patients with PSMA-positive metastatic prostate cancer who are still hormone-sensitive, nearly doubling the eligible patient population from its previous indication for hormone-resistant cases.

Aug 2, 2026·8 sources
00
Jul 24, 2026

FDA Approves Outlook Therapeutics' LYTENAVA as First Branded Bevacizumab for Wet AMD After Fourth Attempt

The U.S. Food and Drug Administration has approved LYTENAVA (bevacizumab-vikg) for treating neovascular age-related macular degeneration (wet AMD), marking the first FDA-approved ophthalmic formulation of bevacizumab after 20 years of off-label use. The approval comes on Outlook Therapeutics' fourth regulatory attempt, though the company faces cash constraints as it enters commercialization.

Jul 24, 2026·8 sources
00

FDA Approves First Over-the-Counter Combination Pill of Tylenol and Naproxen for Pain Relief

The U.S. Food and Drug Administration approved a nonprescription fixed-dose combination pill containing acetaminophen (650 mg) and naproxen sodium (220 mg), marketed as Tylenol with Naproxen by Kenvue. The medication provides up to 12 hours of pain relief for patients aged 12 and older.

Jul 24, 2026·9 sources
00
Jul 16, 2026

Merck wins FDA approval for first oral PCSK9 cholesterol pill

Merck received FDA approval for its oral PCSK9 inhibitor cholesterol pill, the first of its kind, offering a more convenient alternative to existing injectable therapies for high-risk patients.

Jul 16, 2026·4 sources
00
Jul 9, 2026

FDA Approves First Wearable On-Body Injector for Cancer Drug Delivery with Sanofi's Sarclisa

The FDA has approved Sanofi's Sarclisa (isatuximab) for subcutaneous delivery via a wearable on-body injector, marking the first cancer drug to receive approval for this delivery method. The device offers multiple myeloma patients a less burdensome alternative to intravenous infusions.

Jul 9, 2026·6 sources
00
Jul 7, 2026

FDA Approves Vera Therapeutics' TRUTAKNA for IgA Nephropathy Treatment

The U.S. Food and Drug Administration has granted accelerated approval to Vera Therapeutics' drug TRUTAKNA for treating adult patients with primary IgA nephropathy, a potentially life-threatening chronic autoimmune kidney disease. The approval sent Vera's shares up 6.8% in afternoon trading.

Jul 7, 2026·3 sources
00
Jul 2, 2026

FDA Expands Casgevy Gene Therapy Approval to Children as Young as Two with Sickle Cell Disease and Beta Thalassemia

The FDA has approved Vertex Pharmaceuticals' Casgevy (exagamglogene autotemcel) for patients aged two years and older with sickle cell disease and transfusion-dependent beta thalassemia, expanding from the previous minimum age of 12 years. The approval was granted under the agency's Commissioner's National Priority Voucher program.

Jul 2, 2026·3 sources
00
Jun 30, 2026

FDA Approves Orca Bio's TREGZI as First Precision-Engineered Cell Therapy for Blood Cancer Transplants

The U.S. FDA has approved Orca Bio's TREGZI, the first precision-engineered cell therapy for allogeneic transplants in adults with hematological malignancies, designed to reduce stem cell transplant complications.

Jun 30, 2026·7 sources
00
Jun 26, 2026

FDA Approves Viridian Therapeutics' Lumvoa for Thyroid Eye Disease, Creating Competition with Amgen's Tepezza

The U.S. Food and Drug Administration has approved Viridian Therapeutics' Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease, marking the first FDA-approved treatment for the condition and setting up direct competition with Amgen's blockbuster drug Tepezza.

Jun 26, 2026·5 sources
00
Jun 24, 2026

FDA approves Trodelvy for first-line triple-negative breast cancer

The FDA approved sacituzumab govitecan-hziy (Trodelvy) on June 24, 2026, for two indications in adults with triple-negative breast cancer: as monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of advanced disease, offering new options beyond standard chemotherapy.

Jun 24, 2026·3 sources
00
Jun 12, 2026

FDA Approves Belzutifan Plus Pembrolizumab as Adjuvant Therapy for Clear Cell Renal Cell Carcinoma

The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.

Jun 12, 2026·3 sources
00
Jun 9, 2026

FDA approves bemotrizinol, first new sunscreen ingredient in over 25 years

The U.S. Food and Drug Administration on Tuesday approved bemotrizinol as a permitted active ingredient for over-the-counter sunscreens, marking the first new UV filter cleared since the late 1990s. The broad-spectrum ingredient has been widely used in Europe and Asia for years.

Jun 9, 2026·5 sources
00
May 14, 2026

Regenxbio's Duchenne Gene Therapy Succeeds in Clinical Trial, Paving Way for FDA Submission

Regenxbio announced its experimental gene therapy for Duchenne muscular dystrophy succeeded in a clinical trial, enabling the company to move forward with an FDA submission.

May 14, 2026·1 source
00
May 5, 2026

Cytokinetics' Heart Disease Drug Myqorzo Meets Primary Endpoints in Phase 3 Trial for Genetic Heart Condition

Cytokinetics announced its heart disease drug Myqorzo, already approved in one indication, succeeded in meeting twin efficacy goals in a Phase 3 trial for genetic heart disease, potentially boosting future sales.

May 5, 2026·1 source
00
Apr 7, 2026

Biosimilar drugs gain ground in US market with new approvals and market leadership

The FDA approved Ranluspec as the first interchangeable ranibizumab biosimilar, Biocon launched denosumab biosimilars Bosaya and Aukelso in the US, and Celltrion's Truxima became the first Korean biosimilar to lead its segment in US prescriptions.

Apr 7, 2026·3 sources
00

Top claims

  • ▪The FDA approved Roche Holding AG's oral breast cancer pill Wilserdly for patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer
  • ▪The approval of Wilserdly expands Roche Holding AG's footprint in an emerging class of medicines aimed at reshaping treatment for HR-positive breast cancer
  • ▪ESR1 gene mutations indicate that an estrogen receptor-positive breast tumor is developing resistance to standard therapies

People involved

Vinay PrasadDonald TrumpRobert F. Kennedy Jr.

Subtopics

Drug Policy, Pricing & Approval55Drug Approval and Clinical Trials37Clinical trials18Cancer & Oncology16Cancer treatment12Cancer treatment breakthroughs12Pharmaceutical Industry10Pharma9Targeted cancer therapy6Accelerated approval pathways5Cancer Treatment & Therapies5Drug pricing5FDA drug approval process5Gene therapy5Immunotherapy5New drug application (NDA) process5Oncology5Precision medicine5Rare diseases5Autoimmune disease treatments4Biologic therapies4Biotech innovation4Drug development4MRNA vaccine technology4

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories